CTL epitope analogs

ABSTRACT

We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional application of U.S. Ser. No.09/692, 325 filed Oct. 20, 2000, which claims the benefit of U.S.provisional application Serial No. 60/160,633 filed Oct. 20, 1999 andU.S. provisional application Serial No. 60/187,871 filed Mar. 8, 2000.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support in the form ofGrant Nos. CA30206 and CA77544 from the National Cancer Institute. TheUnited States Government may have certain rights to the invention.

BACKGROUND OF THE INVENTION

[0003] 1. Technical Field

[0004] This invention relates to peptide ligands from viruses, e.g.,human cytomegalovirus (HCMV) with improved immunogenicity widerecognition among HLA subtypes and methods for their production. Thesepeptides are able to activate cytotoxic T lymphocytes at extremely lowconcentrations and therefore are suitable for use as vaccines.

[0005] 2. Description of the Background Art

[0006] The HCMV genome is relatively large and has the capacity toencode more than 200 proteins. HCMV is composed of a nuclear complex ofdouble-stranded DNA surrounded by capsid proteins having structural orenzymatic functions, and an external glycopeptide andglycolipid-containing membrane envelope. HCMV is a member of the Herpesvirus family and has been associated with a number of clinicalsyndromes.

[0007] HCMV infection is relatively common and is usually self-limitingin the healthy, immunocompetent child or adult. However, approximately10% of all newborn infants carry HCMV; the virus can cause severecongenital disease in the fetus or infant. For example, HCMV is a commoncause of mental retardation in children who acquire the infection inutero from mothers carrying an active infection. Some of these newborninfants suffer congenital birth defects; others carry cytomegalovirusfor some time before they show symptoms of the disease.

[0008] Other syndromes have been noted in persons carrying a persistentand apparently asymptomatic HCMV infection, for example, restenosis.HCMV is also associated with morbidity and mortality inimmuno-compromised patients, such as patients suffering from acquiredimmunodeficiency syndrome (AIDS). AIDS patients infected with HCMV oftensuffer impairment of some of their vital organs, including the salivaryglands, brain, kidney, liver and lungs as a result of the effects ofHCMV disease. Furthermore, HCMV is associated with a wide spectrum ofclassical syndromes including mononucleosis and interstitial pneumonia.HCMV also has oncogenic potential and possible association with certaintypes of malignancies, including Kaposi's sarcoma.

[0009] Because human cytomegalovirus is relatively common, yet isassociated with some extremely serious health conditions, considerableeffort has been made to study the biology of the virus with the aims ofimproving diagnosis and developing preventive and therapeuticstrategies.

[0010] Viral infection of a host stimulates the processing of viralproteins through the Class I pathway, resulting in antigenic peptideswhich are presented by antigen presenting cells in the context ofcell-surface MHC Class I. A CD8⁺ CTL response is an important part of amammalian host's response to certain acute viral infections.Differentiation of CD8⁺ T cells into mature CTL generally leads toclearance or control of the viral infection. The observations that HCMVinfection is wide-spread and persistent and can become reactivated andclinically important in the immunosuppressed patient, suggest thatvirus-specific T cells, including HCMV-specific CTL, play an importantrole in both the control of persistent infection and recovery from HCMVdisease. In a CD8⁺ CTL response, a processed form of a viral protein (aminimal cytotoxic epitope) is recognized by CD8⁺ CTL in combination withMHC Class I molecules. A minimal cytotoxic epitope of 8-12 amino acidscan prime an antigen presenting cell to be lysed by CD8⁺ CTL, as long asthe correct MHC molecule is expressed on its surface.

[0011] Certain viral structural proteins which exist in large quantityin the viral particle, such as pp65 in HCMV, are chaperoned intoinfected host cells early in infection. Structural virion proteins areimmuno-dominant target antigens important in the production ofHCMV-specific CTL responses. The pp65 protein has been identified as atarget antigen which is present in the peripheral blood of mostasymptomatic HCMV seropositive individuals. McLaughlin-Taylor et al., J.Med. Virol. 43:103-110 (1994). The pp65₄₉₅₋₅₀₃ CTL epitope (SEQ ID NO:1; NLVPMVATV) from HCMV is universally recognized amongHCMV-seropositive individuals who express HLA A*0201. Moreover, CTLagainst pp65₄₉₅₋₅₀₃ recognize and lyse HCMV infected cells in vitrowithin an hour of infection. Thus, these CTL which recognize pp65₄₉₅₋₅₀₃may be important for limiting HCMV reactivation and progression of HCMVdisease. The ability to induce a cellular immune response to pp65therefore is extremely important in protecting both immuno-compromisedand normal individuals from HCMV disease. However, the binding affinityof the pp65₄₉₅₋₅₀₃ epitope to HLA A*0201 is only moderately strong.

[0012] One method of eliciting virus-specific CTL is to immunize with avaccine peptide representing a minimal cytotoxic epitope defined for aviral antigen in the context of a particular MHC restriction element.Such a vaccine boosts the CTL memory response to the virus inindividuals carrying that MHC restriction element. Vaccine developershave become increasingly interested in immunizing with minimal cytotoxicepitopes rather than virus proteins because they can bind to MHC Class Imolecules in the host through direct binding of the cell surfacemolecules without internalization or processing.

[0013] Individual MHC Class I molecules preferentially bind peptides ofa given motif. The amino acid sequence of specific positions of themotif known as “anchor positions” are invariant. Falk et al., Nature351:290-296 (1991). Amino acid positions other than the anchor positionalso contribute to a lesser degree to the specificity of peptide bindingto MHC Class I molecules. Additionally, residues at positions within theCTL epitope which do not interact with MHC may interact with T cells.Some amino acid residues of the epitope contact the T cell receptor ofthe responding T cell, some contact the MHC restricting allele expressedon an antigen presenting cell, and some do not strongly contact either.Fremont et al., Science 257:919-927 (1992); Madden et al., Cell75:693-708 (1993); Ono et al., J. Immunol. 161:5454-5463 (1998). Thebinding of amino acid residues to MHC or T cell receptor structures isindependently governed, so that substitution of T cell receptor bindingamino acid residues in some cases will not interfere with the binding tothe MHC molecule on the surface of an antigen presenting cell. Sette etal., Mol. Immunol. 31:813-822 (1994); Vierboom et al., J. Immunother.21:399-408 (1998); Valmori et al., J. Immunol. 161:6956-6962 (1998).

[0014] Peptides from the melanoma-specific antigen gp-100 have beenaltered at the anchor positions for increased binding to HLA A*0201,which resulted in the increased efficiency of stimulation of CTL frommelanoma patients. Parkhurst et al., J. Immunol. 157:2539-2548 (1996).Similarly, CTL epitopes specific for murine H-2 Kd, Kb and Db weresubstituted at anchor positions, resulting in enhanced immunogenicity.Vierboom et al., J. Immunother. 21:399-408 (1998). On the other hand,directed substitution at anchor positions did not produce ligands thatstimulated high-affinity CTL directed toward cancer antigens which wereable to cause tumor regression. Clay et al., J. Immunol. 162:1749-1755(1999). Therefore, different approaches need to be considered indefining residue substitutions that might influence the immunogenicityand vaccine properties of the pp65₄₉₅₋₅₀₃ CTL epitope. The complexity ofthe molecular interactions between the individual molecular componentsof the immune system complex (TCR, peptide and MHC) has thwarted mostattempts at significantly enhancing the binding affinity andimmunogenicity of most peptide MHC ligands. Clay et al., J. Immunol.162:1749-1755 (1999); Parkhurst et al., J. Immunol. 157:2539-2548(1996); Leggatt et al., J. Immunol. 161:4728-4735 (1998).

[0015] In most cases, CTL epitopes are between 8-11 amino acids long asdetermined by either mass spectrometry or Edman degradation of peptideseluted from MHC molecules. Peptides which bind to MHC molecules afterinfection with virus are referred to as “naturally processed epitopes.”These peptides require no further proteolytic processing to sensitizethe transporter for antigen processing (TAP) deficient cell line, T2,for CTL-mediated lysis. Synthetic peptides having the sequence of theseminimal length peptides (and certain variants) also can bind to MHCmolecules and sensitize targets for lysis by CD8⁺ CTL. Rammensee et al.,Annu. Rev. Immunol. 11:213-244 (1993). More importantly, these peptidesare capable of eliciting CTL that control or clear viral infections. Delet al., J. Virol. 65:3641-3646 (1991); Schulz et al., Proc. Natl. Acad.Sci. USA 88:991-993 (1991). An important objective therefore is todevelop vaccination strategies that will successfully combat diseaseutilizing CTL epitopes or their analogs.

SUMMARY OF THE INVENTION

[0016] Accordingly, this invention comprises a method of producing ahuman cytomegalovirus peptide cytotoxic T lymphocyte epitope analog withimproved immunogenic potency and retained breadth of recognition of MHCallele subtypes relative to the native human cytomegalovirus peptidecytotoxic T lymphocyte epitope which comprises providing a sequence of ahuman cytomegalovirus peptide cytotoxic T lymphocyte epitope and acombinatorial peptide library which contains peptide analogs of saidviral peptide cytotoxic T lymphocyte epitope; screening saidcombinatorial peptide library for immunogenicity; analyzing the resultsof said screening to select one or more peptide analogs which may haveimproved immunogenicity relative to the native human cytomegaloviruspeptide cytotoxic T lymphocyte epitope; assaying said one or morepeptide analogs for immunogenicity; analyzing the results of the assayin step (d); selecting one or more highly immunogenic peptide analogsbased on the analysis of step (e); assaying said highly immunogenicpeptide analogs for broad recognition of MHC allele subtypes; analyzingthe results of the assay in step (g); selecting one or more highlyimmunogenic peptide analogs with retained breadth of recognition of MHCallele subtypes relative to the native human cytomegalovirus peptidecytotoxic T lymphocyte epitope based on the analysis of the earliersteps; and synthesizing the peptides selected in step (i). In anotherembodiment, the invention provides a method which further comprises,before synthesizing the peptides, creating a library of peptide analogsfrom the highly immunogenic peptide analogs of step (f) containingsubstitutions of the native viral peptide cytotoxic T lymphocyteepitope; assaying said library of peptide analogs containingsubstitutions of the native viral peptide cytotoxic T lymphocyte epitopefor both immunogenicity and breadth of recognition of MHC allelesubtypes; and analyzing the results of the assays in step (B).

[0017] In further embodiments, the invention provides cytotoxic Tlymphocyte epitope analogs produced according to the methods describedabove, for example, SEQ ID NOS: 38, 52 and 64. In further embodiments,the invention provides vaccines comprising such peptides.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018]FIG. 1 is a bar graph presenting cytotoxicity data for antigenpresenting cells loaded with the indicated carboxyl terminal amidatedpeptides.

[0019]FIG. 2 is a bar graph presenting cytotoxicity data for antigenpresenting cells loaded with the indicated carboxyl terminal acidpeptides.

[0020]FIG. 3 is a series of bar graphs presenting cytotoxicity resultsfrom a nomoner PS-SCL screening assay. Panels A through I present datafrom peptide positions 1 through 9, respectively. The residue present inthe native sequence at each position is represented by a hatched bar,while the remaining amino acids are represented by solid bars.

[0021]FIG. 4 is a bar graph showing specific fluorescence indicatingbinding of the indicated peptides to 3-3F4 and VB57.

[0022]FIG. 5 is a pair of bar graphs providing data regarding HCMV CTLepitope recognition by HCMV seropositive donors.

[0023]FIG. 6 provides data regarding the recognition of three differentCTL peptide analogs by HCMV seropositive donor CTL.

[0024]FIG. 7 is a bar graph showing the results of a T2 assembly assay.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Multiple TCR sequences are used to recognize the native viralsequences such as pp65₄₉₅₋₅₀₃ by different individuals. Solache et al.,J. Immunol. 163:5512-5518 (1999); Weekes et al., J. Virol. 73:2099-2108(1999). It is of great interest to understand what common elements ofnative sequences allow them to be recognized by individuals with diverseTCR repertoires, as a means to design universally recognizable CTLepitope analogs of higher immunogenicity in the context of fighting aviral infection such as HCMV. Whether vaccine peptides can maintain anequivalent breadth of recognition as the native peptide sequence (i.e.,pp65₄₉₅₋₅₀₃) is an important criterion for their value to the publichealth. If vaccine peptides are only recognized by a small subset ofindividuals, then their usefulness is limited. The immunodominance ofviral peptides like pp65₄₉₅₋₅₀₃ provides a circumstance in which carefulselection of residues can produce a peptide which provides both maximumimmunogenic effect and very wide recognition.

[0026] Preferably, antiviral vaccines should suppress both primaryinfection and reactivation of persistent or latent virus. A robusthumoral response to major surface glycoproteins may be adequate toprevent new infection, but usually will not prevent reactivation oflatent virus, which is spread through cell-cell contact. A cellularimmune response capable of lysing infected cells which destroys theintracellular store of virus, therefore, is a goal of any vaccinestrategy, and particularly for HCMV.

[0027] Once HCMV infection is established, HCMV persists throughoutlife. Healthy HCMV-seropositive adults maintain a large fraction ofcirculating CTL with specificity against the virus but the virus is notcleared. Interference with antigen presentation may limit theeffectiveness of ongoing adaptive immunity. Nonetheless, viremia isseldom found in asymptomatic seropositive donors. In contrast,individuals who are immunosuppressed after bone marrow transplantationor virus infection (e.g., HIV) often have active HCMV viremia.Augmentation of viral immunity by eliciting greater numbers of CTL, morepotent CTL or both would limit viremia and prevent disease to a largeextent. Because pp65 is the main target of cellular immunity inasymptomatic adults, a vaccine against HCMV will likely need to enhanceimmunity against pp65 to be successful. Enhancing the immunogenicity ofCTL epitopes from pp65 which are recognized by the adaptive immunesystem is a potent strategy to overcome HCMV viremia and disease.

[0028] Peptide ligands such as pp65₄₉₅₋₅₀₃ can activate CTL for targetlysis with a sensitivity in the nanomolar range. Diamond et al., Blood90:1751-1767 (1997). Some other CTL epitopes derived from pp65 or otherviral proteins can sensitize lysis of antigen presenting cells in thepicomolar range, however these more potent viral proteins often are notrecognized as frequently by large human populations. Busch et al., J.Immunol. 160:4441-4448 (1998); Gallimore et al., J. Exp. Med.187:1647-1657 (1998); Vierboom et al., J. Immunother. 21:399-408 (1998).It would be advantageous to develop a CTL epitope which retains nearuniversal recognition and yet has enhanced immunogenicity. This wouldimprove the effectiveness of anti-viral peptide vaccines and reduce theamount of peptide needed to obtain a clinically relevant immuneresponse. To be of greatest clinical value from a public healthperspective, the vaccine peptide analog would preferably retain theability to be recognized and to stimulate CTL expressing most or allsubtypes of the appropriate HLA group, for example HLA A*0201.Therefore, the terms “immunogenic,” “immunogenicity” or “immunogenicpotency” refer to the ability to stimulate cytotoxic T lymphocytes at arelatively low concentration. The term “retained breadth of recognitionof MHC allele subtypes” refers to the ability of the epitope to berecognized by a range of cytotoxic T lymphocytes possessing differentMHC allele subtypes.

[0029] In vitro stimulation was employed to establish the extent ofrecognition of the pp65₄₉₅₋₅₀₃ epitope among seropositive HLA A*0201individuals and further confirm that pp65₄₉₅₋₅₀₃ epitopes can stimulateCTL that will recognize HCMV-infected fibroblasts. A survey of 10individuals confirmed its wide recognition. Since there is littlenatural variation of the pp65₄₉₅₋₅₀₃ sequence at any of the ninepositions, there is no easy way to predict the tolerance of amino acidsequence modification of the epitope.

[0030] To predict the immunogenic potency effect of extensive amino acidresidue changes in a CTL peptide epitope, it is useful to begin byidentifying which amino acid residues may be changed without reducingimmunogenicity. An alanine substitution study, for example, allows oneto perform such a study quickly and easily. To perform this type ofstudy, a series of peptides may be synthesized which contain an alaninesubstitution at each different position along the sequence to be tested.For example, Table I shows the structure of alanine-substituted peptidesfor use in an alanine-substitution study of the native residues in eachposition of pp65₄₉₅₋₅₀₃ (SEQ ID NO:1; NLVPMVATV). Eachalanine-substituted peptide may be synthesized with either a free acidcarboxyl terminus or an amide terminus or both may be synthesized. Thepeptides then may be used to sensitive antigen presenting cells, whichcan be screened for lysis by the T cell clone of interest. Of course,substitution may be made with alternative amino acids if convenient.Those of skill in the art of peptide design and combinatorial chemistryare well aware of different methods to investigate the effects ofresidue substitutions, and these are contemplated for use here.

[0031] It is useful to screen different peptides for cellularimmunogenicity or the ability to lyse antigen presenting cells whichpresent the viral epitope. An efficient way to accomplish this is toscreen a peptide library. The combinatorial chemistry approach ispreferred, however those of skill in the art are aware of many methodsto obtain and test a number of peptides. A more robust approach thansingle amino acid substitution makes use of combinatorial chemistry toproduce simultaneous large arrays of multiply-substituted peptides. Thelibrary approach for studying T cell epitopes can be combined withinformation gained from MHC anchor studies, or alanine substitution. Aconvenient method to screen a large number of peptides to obtaininformation allowing a correlation of immunogenicity and changes inpeptide sequence at specific locations is through a positional scanningsynthetic combinatorial library.

[0032] An important attribute of a PS-SCL sub-library to simultaneouslyscan all possible residue combinations at all positions of an epitope,which may predict a better choice than a directed amino acidsubstitution at a single position. Recent studies utilizing thepositional scanning format have identified high potency ligands whichexceed the binding affinity of the natural ligand. The focus of theseprevious reports has been either to discover new epitopes, or enhanceexisting epitope immunogenicity specific to individual inbred mousestrains, or human T cell clone. Gundlach et al., J. Immunol.156:3645-3651 (1996); Hemmer et al., J. Immunol. 160:3631-3636 (1998);Wilson et al., J. Immunol. 163:6424-6434 (1999). Restricted versus broadrecognition of the analog epitopes has not been the main concern ofprevious studies. In contrast, this invention provides a method ofenhancing immunogenicity of a CTL epitope simultaneously preserving thedesirable property of universal recognition. Both are necessaryproperties of a vaccine for broad clinical use.

[0033] Positional scanning synthetic combinatorial libraries (PS-SCL)are libraries composed of peptides of uniform length having specificdefined positional mutations systematically arranged. A typical PS-SCLcomprises a positional sub-library for each position along the length ofthe peptide. For example, a nonamer PS-SCL comprises nine independentpositional libraries, and is represented as O₁XXXXXXXX, XO₂XXXXXXX,XXO₃XXXXXX, XXXO₄XXXXX, XXXXO₅XXXX, XXXXXO₆XXX, XXXXXXO₇, XX,XXXXXXXO₈X, XXXXXXXXOg in which O₁-O₉ each represent a position occupiedby a defined amino acid, and X represents positions occupied by anyamino acid. An octomer PS-SCL comprises eight positional libraries. Eachpositional library in the PS-SCL comprises 20 sublibraries in which the“O” position is occupied by a different defined amino acid. Thescreening of a PS-SCL can provide information about the most importantresidues at each position of the CTL epitope for strong recognition by aT cell clone.

[0034] The length of the epitope specific for a T cell clone is astarting point in selecting an appropriate peptide screening library.For example, the CTL epitope for T cell clone 3-3F4 (pp65₄₉₅₋₅₀₃; SEQ IDNO:1) is a nonamer, therefore a nonamer peptide PS-SCL was selected.Generally, library sub-mixtures for screening are used at a low enoughconcentration, for example 50-100 μg/mL, such that individual peptidesin the sub-mixture are present in vanishingly small amounts (˜5.5×10⁻¹⁵M). Greater or lower concentrations of library peptides may be used asis convenient, depending on the parameters of the screening assay used,however about 10 μg/mL to about 1 mg/mL is preferred and about 50 μg/mLto about 100 μg/mL is most preferred. Even though each individualpeptide in the mixture is present in very low concentration, cytotoxicactivity against sensitized antigen presenting cells is measurable.Measurable cytotoxic activity indicates that one or more individualpeptide analogs in the mixture nevertheless can trigger T cellresponses.

[0035] The peptide library is conveniently screened by preparing antigenpresenting cells expressing the peptides on their surfaces. Theseantigen presenting cells can then be loaded with ⁵¹Cr and assayed forlysis by T cells derived from asymptomatic virus seropositive blooddonors who have mounted a cellular immune response to the virus. Thesub-mixtures within the library may be screened to determine whichgroups of peptides result in the greatest cytotoxicity of antigenpresenting cells. Once the group or groups of most active peptides aredetermined, individual peptides advantageously may be synthesized toconfirm the results obtained from the screen.

[0036] Preparatory experiments with the T cell clones preferably may becarried out to establish the minimal concentration of native peptideligand which causes sufficient lysis of the HLA-matched antigenpresenting cells. A T cell clone that recognizes the peptide bound tolymphocytic cell lines (LCL) advantageously may be used to conducttitration experiments using a limiting number of antigen presentingcells which cause optimal recognition by the peptide at a givenconcentration.

[0037] Peptides may be synthesized by any convenient method known in theart. The peptides are advantageously tested for immunogenicity byassaying lysis of antigen presenting cells presenting the peptides orvirus-infected cells. Antigen presenting cells, for example peripheralblood mononuclear cells, dentritic cells or an Epstein-Barr virusimmortalized lymphocyte B-cell line, may be obtained by prior artmethods such as density gradient centrifugation and the like from anyconvenient tissue, however peripheral blood is most convenient. Othertissues also may be useful. Culture techniques for maintaining any ofthese antigen presenting cells are well known in the art and may beadapted according to the cell type chosen.

[0038] Antigen presenting cells may be pulsed with peptide by knownmethods, or any method. Generally, cells may be incubated for about 4 toabout 6 hours or for about 2-3 hours with the peptide to be presented. Afinal peptide concentration of about 100 μM is suitable, however thismay vary. About 1 μM to about 500 μM typically can be used. Afterincubation with the peptide(s), the cells are advantageously exposed togamma irradiation. About 2,400 rads is sufficient, or any amount tocause the death of the feeder or target cells within about 1-2 daysafter exposure. Radiation is titrated for individual cell types. Forexample, typically, 2,500 rads is used for mononuclear cells and up to5,000 rads is used for lymphoid blast lines or cultured lines, varyingupon the sensitivity of the cells to radiation.

[0039] Screening assays to determine whether the peptides elicit acellular immune response directed by virus specific cytotoxic Tlymphocytes as known in the prior art are conveniently used. The targetcells (antigen presenting cells) described above may be screened forlysis by T cell clones specific for the virus (effector cells). These Tcell clones may be prepared from peripheral blood mononuclear cells fromhealthy virus seropositive blood donors. The cells may be depleted ofCD4+, CD16+ and CD56+ cells by any method known in the art, such as byimmunomagnetic separation using specific antibodies, and the like.Alternatively, CD8⁺ cells may be purified by direct immunoseparation, orby any convenient method. These purified or semi-purified CTL may bekept in culture and used as a source of virus specific T cell clones. Invitro stimulation of the T cell cultures with gamma-irradiated fresh,allogeneic peripheral blood mononuclear cells and PHA causesproliferation of the specific T cell clones. A combination of limitingdilution and in vitro stimulation allows the desired clones to beexpanded.

[0040] For a suitable assay of cytotoxicity, chromium release assays areconvenient. Target antigen presenting cells may be loaded with ⁵¹Cr andexposed to the virus-specific CTL. Virus-infected fibroblasts, T2 cells,or any convenient cell may be used as a target, as well as antigenpresenting cells loaded with CTL epitope peptides or analogs. Afterlabeling with ⁵¹Cr, the target and effector cells are mixed togetherwith culture and incubated for several hours, for example about 2 toabout 16 hours, or about 2 to about 8 hours, or most preferably forabout 4 hours. After the incubation, the amount of chromium releasedfrom the cells is measured. Generally, it is greatly preferred toperform control incubations to test spontaneous release in the absenceof effector cells and maximal total release as controls with each assayperformed.

[0041] When the candidate vaccine peptides or library peptides have beenscreened, peptides or peptide groups which have resulted in significantimmunogenicity may be individually screened in the same manner toconfirm activity. Additional assays may be performed with individualpeptides if desired. For the specific peptides exemplified here, analanine substitution study was performed using the peptides of Table Ito determine which amino acids could be changed without losing therecognition needed for cell recognition and cytolysis or which aminoacid residues were more flexible in their binding.

[0042] In the alanine substitution study, the amidated forms showedprominent recognition differences from their free acid-counterparts,especially at the termini of the epitope. Only slight differences wereobserved in recognition between the native sequence and analogs withalanine substitution at positions 1, 8, and 9. The data suggested thosepositions to be tolerant of amino acid substitutions and that theamidated carboxyl terminus uniformly enhanced recognition andsensitivity compared to the free acid forms of the analogs. The resultsof this study were compared to the results of a comprehensive screen ofpeptides using a positional scanning synthetic combinatorial library.

[0043] The screening of the positional libraries pointed to several CTLpeptide epitope analogs which resulted in greater cytotoxicity than thenative peptide by chromium release assay. The results for positions 1,3, 7, and 8 were particularly interesting. The favored defined aminoacid sub-library for each of those positions was non-intuitive, based onpublished motif information; despite showing minimal change inrecognition, alanine substitution at positions 1, 3, 8 and 9 was notpredictive whether an alanine defined amino acid library from the PS-SCLwould be well recognized. Since the sub-libraries are composed ofdiverse sequences whose only similarity is the single fixed amino acidat one position, linking superior recognition of a positional library tosuperior recognition of a single peptide sequence in the mixture cannotbe made directly. One consistent property of the alanine and PS-SCLscreens was the advantage of C-terminal amidation to obtain high levelrecognition of analogs.

[0044] Sequences corresponding to the best recognized defined amino acidlibrary at each of nine positions were selected, and 16 peptides weresynthesized as both amidated and free acid forms. Choices of amino acidsfor positions 1 and 2 were difficult to select, because the differencesbetween sub-libraries was minimal. Since the native peptide is extremelyhydrophobic, a decision to avoid phenylalanine in positions 1 and 2 infavor of tyrosine and leucine, respectively. Only two of the 16predicted peptides were significantly more immunogenic than the nativesequence. In 3 of 4 instances in which two amino acids were evaluated atone position, only one provided any benefit to immunogenicity, and insome cases, the alternative proved to be deleterious for recognition orequally tolerated. Significantly, the free acid forms of all 16 peptidesproved to be non-immunogenic utilizing either T2 cells or Epstein-Barrvirus transformed B cells. In contrast, there was no difference inimmunogenicity between the amidated and free acid forms of the nativeepitope sequence.

[0045] Peptides 44N and 46N (YLLPMVVSV-NH₂ and YLLPMVTSV-NH₂; SEQ IDNOS:2 and 3; see Table II) were assayed individually and found to havegreater cytotoxicity, but to have lost the property of wide recognitionby different subtypes of HLA A*0201. No T cell clone other than 3-3F4recognized peptides 44N and 46N, even when antigen presenting cells weresensitized at 5 nM, a saturating concentration for the native sequence.Since the analogs were not cross-reactive with T cell clones specificfor the native sequence, the peptides were evaluated by in vitrostimulation to determine whether any distinct memory T cell clonespecific for peptides 44 and 46 could be stimulated from peripheralblood. Although peripheral blood from four individuals who responded tothe native epitope sequence were stimulated with peptides 44 and 46,only T cells from the individual from whom the PS-SCL screen clone wasderived showed any positive response. These results suggest that peptideT cell receptor contacts were altered by insertion of new residues atpositions 1, 3, 7, and 8 and it is likely that peptides 44 and 46 arerecognized by only a small number of TCR sequences.

[0046] To regain the wide recognition of the native sequence, thepeptides were modified by substituting back one or more of the nativeresidues as shown in Table IV. These peptides were screened for lysis byseveral different T cell clones and were found to have regained ameasure of the wide recognition enjoyed by the native sequence whileretaining the potency of the first peptide analogs. See Table V.

[0047] The data showed that restricting the modifications of the nativeCTL epitope sequence enabled the design of a more universally recognizedpeptide than the peptides of SEQ ID NOS:2 and 3. One of the peptidesdemonstrated which is still of greater immunogenicity than the nativepeptide sequence. The success of these recognition studies in a smallcohort of individuals with diverse haplotypes demonstrates thefeasibility of these methods in creating improved vaccine peptides whichpossess both wide recognition and high potency.

[0048] Several peptides derived from substitutions of the naturallyprocessed epitope are more immunogenic than the native peptide sequence.The basis for the increase may be related to a change of affinity toeither MHC Class I or the TCR. Changes to MHC Class I binding of CTLepitopes can be measured independently from changes in TCR bindingaffinity using the T2 assembly assay, which measures the relativestrength of peptide binding to HLA A*0201. Nijman et al., Eur. J.Immunol. 23:1215-1219 (1993); Sette et al., J. Immunol. 153:5586-5592(1994); Zeh et al., Hum. Immunol. 39:79-86 (1994). A selection ofpeptides in both amidated and free acid forms were subjected to the T2assembly assay.

[0049] Peptide binding to MHC Class I measured via the T2-assembly assayonly partially correlated with the increased killing activity of keyanalogs. The forms of peptides 44 and 46 demonstrated substantialbinding differences. The contrast between acid and amide forms inbinding to HLA A*0201 is not as pronounced for the three moreuniversally recognized analogs (118, 115, and 193). Heightenedrecognition of the antigen analogs, therefore, is not based solely uponincreased affinity to MHC Class I. More likely, the PS-SCL libraryscreening selected peptides having alterations of TCR contact residuesthat contribute to heightened affinity.

[0050] Previous studies have not addressed the concept of improvingimmunogenicity of epitopes while maintaining broad recognition. Studieswhich optimize anchor residues of CTL epitopes do not alter T cellcontacts since anchor positions mainly bind to MHC Class I. Approacheswhich have focused strictly on anchor residues, therefore, withoutregard to other peptide contacts with TCR or MHC have not resulted indramatic increases in immunogenicity. The degree of flexibility ofsubstitutions at position 1, which tolerated tyrosine in place ofasparagine, was not predicted by published motifs, and highlights thestrength of the library approach.

[0051] An approach to distinguishing how particular substitutions of TCRcontact residues contribute to the heightened immunogenicity of analogpeptides of pp65₄₉₅₋₅₀₃ is to utilize a soluble HLA reagent that onlyrecognizes TCR after binding specific peptide using an HLA-Ig dimer. Seethe methods of Carruth et al., AIDS Res. Hum. Retroviruses 15:1021-1034,(1999) and Greten et al., Proc. Natl. Acad. Sci. USA 95:7568-7573(1998). The dimer reagent is a chimera of the HLA Class I α1 and α2domains attached to the Fab portions of Ig molecules. It specificallylabels T cells (from T cell clones or from diverse PBL populations) incombination with specific peptide epitopes from either human or murinesources. Bieganowska et al., J. Immunol. 162:1765-1771 (1999); Lebowitzet al., Cell. Immunol. 192:175-184 (1999).

[0052] Peptide analogs were evaluated using a T cell clone withrecognition of pp65₄₉₅₋₅₀₃ equivalent to 3-3F4, but expressing a uniqueTCR. Three analogs showed 10-30 fold greater immunogenicity than thenative sequence (Tables IV and V). The data suggested that a combinationof two peptides (118N and 193N) would be more immunogenic and broadlyrecognized than the native sequence. The failure of all three peptidesto be recognized as universally as the native epitope sequence bycross-reactive T cell clone was not unexpected.

[0053] To examine whether a separate repertoire exists that recognizesanalogs in different individuals, the recognition of the three epitopesthat were cross-reactive to T cell clone VB57 were examined by in vitrostimulation, an approach that proved effective for evaluating the nativesequence epitope and 44 and 46. The results confirmed that of the threepeptides, 118N and 193N were most broadly recognized, and 115N had morelimited recognition. Furthermore, all three analogs expanded peripheralblood CTL that not only recognized peptide coated targets, but were ableto independently lyse HCMV-infected fibroblasts. In summary, the IVSresults are consistent with broad-based recognition Qf two out of threeof the analogs. Analogs 118N and 115N have properties that qualify themas vaccines because they are more immunogenic than the native epitope,but are likely recognized by as extensive a population as the nativeepitope.

[0054] Peptides according to the invention may be formulated as vaccinesaccording to any suitable method. Naked peptides may be formulated in asuitable adjuvant or any other pharmaceutically acceptable carrier.Cellular vaccines may be prepared by any known method. HCMV peptidesaccording to the invention may be administered alone, or together with ahelper peptide such as the polyclonal helper T lymphocyte peptide,PADRE. The two peptides may be administered together or separately, butit is preferable to administer them in close time proximity.

[0055] Alternative vaccines include fusions of the helper CD4 peptideepitope with the CTL epitope. The peptides may be fused in either orderand may contain a linker sequence between them if desired. Examples ofhelper CD4 epitopes are the synthetic sequence PADRE (J. Alexander etal., Immunity 1:751-761 (1994)) and tetanus-specific peptides. In somecases, these fusion peptides may not require additional covalent lipidmodification or adjuvant when administered by the subcutaneous,intranasal, intraperitoneal or intravenous routes. Alternatively, singlestranded DNA containing CpG motifs may be co-administered to provideincreased activity of the fusion peptide when simultaneously provided atlimiting concentration.

[0056] A preferred alternative is to join the antigenic peptide to PADREsuch that the two sequences form a single peptide chain. PADRE may bepositioned at the N- or C-terminus of the antigenic HCMV peptide, and alinker sequence may be positioned between the two sequences or in frontof the N-terminal sequence, if desired.

[0057] Peptides of the invention may be lipidated or may lack lipids.Unlipidated peptides, whether incorporating a helper peptide sequence ornot, are contemplated by the invention, as are monolipidated,dilipidated or trilipidated peptide vaccines. Suitable lipids which maybe linked to the peptide sequence include, but are not limited topalmitic acid, stearic acid, myristic acid, lauric acid, capric acid,decanoic acid and the like. Lipids may be attached to the peptides atany location and by any convenient method known in the art.

[0058] Adjuvants may form part of the vaccine formulation. Adjuvantssuch as complete or incomplete Freund's adjuvant, aluminum hydroxide orthe like are contemplated, however a preferred adjuvant, particularlyfor use in humans, is a DNA adjuvant. Single-stranded DNA adjuvantscomprising specific sequences including Cytosine-phosphate-Guanosine(CpG) are known in the art and are contemplated for use with thisinvention. DNA adjuvants lacking these CpG sequences also are usefulwith the invention. An exemplary DNA adjuvant may comprise a 20mer ofnucleotides with 2 CpG motifs, or any DNA oligomer, generally about 20to about 25 nucleotides long. Increased stability of the sequence may beobtained by substituting phosphate groups in the nucleotide backbonewith thio groups to create a phosphoro-thioate backbone rather than aphosphoro-diester backbone.

[0059] The following non-limiting examples are included to illustratethe invention.

EXAMPLES Example 1 Peptide Synthesis and Characterization

[0060] The alanine-scan acid termini peptides (Table I) were synthesizedon a Pioneer Peptide Synthesizer with MPS Accessory (PerseptiveBiosystems, Foster City, Calif.) at 0.05 mmol scale using Fmoc-L-ValPEG-PS resin and standard L-Fmoc amino acids with HATU/DIPEA activators.The peptide 44/46 amidated sublibrary (Table IV) was synthesized usingstandard Fmoc protocols, using a Synergy (Perseptive Biosystems 432A,Foster City, Calif.) at 0.025 mmole scale. Amidated peptides weresynthesized using the Fmoc protected Val-Rink Amide-MBHA resin (AnaSpecInc., San Jose, Calif.). The peptide 44/46 free acid sub-library (TableIV) also was synthesized as described above using Fmoc Val Wang Resin(AnaSpec Inc., San Jose, Calif.). The Fmoc L-amino acids used in allsyntheses were purchased from Novabiochem (San Diego, Calif.) andPerseptive Biosystems (Foster City, Calif.). Fmoc-tyrosine, serine, andthreonine had t-butyl side chain protection and asparagine had tritylside chain protection.

[0061] All peptides were cleaved from the resin and purified accordingto prior art methods (39). To verify correct mass of the peptide, MatrixAssisted Laser Desorption Ionization Mass Spectrometry (MALDI) wasperformed on the Kompact Probe (Kratos Analytical, Manchester, UK). HPLC(Shimadzu SCL 10AVP) using a C₁₈ column of 4.6×250 mm dimension composedof 5μ×300Δ particles (Vydac Separations, Hesperia, Calif.) also wasperformed. Sample purity was assessed at 70-80% based on the areapercent of the sample peak in the chromatogram. The native pp65₄₉₅₋₅₀₃epitope was purchased from Peninsula Laboratories Inc. (San Carlos,Calif.) at a purity of 95% established by HPLC.

Example 2 Preparation of Peptide-Loaded Antigen Presenting Cells and InVitro Stimulation

[0062] Peptide loaded antigen presenting cells were prepared as follows.Sixty milliliters of human blood was collected in sodium heparin fromhealthy donors who were serologically typed as HLA A*0201 and HCMVpositive. Donors were first screened for HLA type (COH HLA Typinglaboratory or National Marrow Donor program) and were subsequentlytested for HCMV seropositivity by indirect immunofluorescence (HemagenDiagnostic, Columbia, Md.). Peripheral blood mononuclear cells wereseparated using Ficoll-Paque™ (Amersham Pharmacia, Uppsala, Sweden), andcells were resuspended in phosphate-buffered saline (PBS) and washed twotimes.

[0063] Sixteen to twenty-four million of the ficoll-separated peripheralblood mononuclear cells were incubated 2-3 hours at 37° C. in a 5% CO₂incubator with 100 μM HCMV pp65₄₉₅₋₅₀₃ peptide (SEQ ID NO: 1) in avolume of 100 μl of T cell culture medium (IVSTCM). IVSTCM consists ofRPMI-1640 supplemented with 20% heat inactivated HAB serum, 10 IU/mlr-IL2 (Chiron, Emeryville, Calif.); 25 mM Hepes Buffer Solution, 50 U/mlpenicillin, 50 μg/ml streptomycin, 2 mM L-glutamine and 0.5 mM sodiumpyruvate (Gibco, Rockville, Md.). Human AB⁺ and HCMV seronegative serum(HAB) for IVS studies was obtained from plasma screened for blood groupand HCMV status. Extraction of serum from plasma was performed followingstandard techniques. Pooled HAB serum was heat inactivated at 56° C. for30 minutes, tested for its ability to support T cell growth, and storedat −20° C. After the incubation period, the cells, now presentingpp65₄₉₅₋₅₀₃ were resuspended in 2 ml IVSTCM, and γ-irradiated (2,400rads) using the Isomedic Model 19 Gammator (Nuclear Canada, Parsippany,N.J.).

[0064] During the peptide incorporation procedure, an additional aliquotof 10-20 million cells from the same freshly separated peripheral bloodmononuclear cells was depleted of CD4+, CD16+, and CD56+ cells asfollows. The cells were incubated with purified mouse anti-human CD4,CD16 and CD56 monoclonal antibodies (mAB) (Pharmingen, San Diego,Calif.) at 10 fold of their saturating concentration, for one hour, withgentle mixing at 4° C. M450 Dynabead goat anti-mouse IgG (Dynal, Oslo,Norway) were then added to the mAb labeled PBMC to effect indirectimmunomagnetic separation. The resulting population was >80% CD8⁺ asdetermined using a FACSCalbur™ fluorescence activated cell sorter (BDImmunocytometry Systems, Palo Alto, Calif.). These depleted PBMCeffectors (200,000 cells ml) were mixed with an equal amount of antigenpresenting cells (5 million cells/ml), and plated in a 24-well plate at2 ml/well. The CTL effectors were incubated at 37° C., in a 5% CO₂incubator for two weeks. They were fed with 10 IU/ml rIL-2 on days 5 and10, and fresh medium when necessary.

Example 3 Derivation of HCMV-Specific T cell Clones Using LimitingDilution from IVS Cultures

[0065] HCMV specific T cell clones were obtained by limiting dilutionfrom the stimulated CTL generated in Example 2. Frozen or fresh cellsfrom the cultures obtained in Example 2 were plated in 96-well U-bottomplates on day 15 of culture at a concentration of 1 or 3 cells/welltogether with 150,000 γ-irradiated fresh allogeneic peripheral bloodmononuclear cells and 0.5 μg/ml phytohemagglutinin (Murex, Dartford, UK)in a final volume of 150 μl of T cell cloning medium (20). After 14days, proliferating cells from single wells were transferred into singlewells of 24-well plates and restimulated a second time with 1million/well/ml fresh irradiated allogeneic PBMC and PHA as describedabove. Starting from day 8 after the second restimulation, activelyexpanding clones (5 to 30 million cells) were tested in a chromiumrelease assay for the ability to specifically lyse cells.

Example 4 Chromium Release Assay

[0066] Chromium release assays were performed according to the methodsof (20). Briefly, target cell lines (antigen presenting cells whichpresent pp65₄₉₅₋₅₀₃) were labeled for one hour with 200 μCi/ml ⁵¹Cr(ICN, Costa Mesa, Calif.). HCMV infected targets were prepared asfollows. Five-hundred thousand fibroblasts were pretreated with 800U/10⁶ recombinant IFN-γ, (Preprotech, Rocky Hill, N.J.) to upregulateMHC class I expression and HCMV was added at an m.o.i. of 4. Cells wereincubated with virus for two hours at 37° C., in a 5% CO₂ incubator.Fresh FBM containing IFN-γ was then added and the cells incubated for anadditional 14 hours. Infected fibroblasts were trypsinized, labeled with⁵¹Cr as described above and used in the assay at an effector-to-targetratio (E/T) of 50 and 10. Epstein-Barr virus transformed B cell lines(EBVLCL) were generated following standard technology using thesupernatant of EBV-infected marmoset cells. EBVLCL were grown in mediumconsisting of RPMI-1640 (Gibco, Rockville, Md.) supplemented with 10%FBS, 10 mM Hepes Buffer Solution (Irvine Scientific, Santa Ana, Calif.),penicillin, streptomycin and L-glutamine as described for fibroblastmedium. The cells used as targets were prepared by pulsing with 50 μmpp65₄₉₅₋₅₀₃ peptide, and used at an E/T of 25 and 5. For PS-SCLscreening and titration of analog peptides, T2 cells, maintained asdescribed in Diamond et al., Blood 90:1751-1767 (1997), were pulsed withserial peptide dilutions for use as targets for T cell clone effectorsat an E/T of 5.

[0067] In the assay, loaded targets and effectors were mixed in cultureand incubated for four hours, at which time chromium release wasmeasured. Supernatants were collected on filter frames (SKATRON, Oslo,Norway) and radioactivity determined in a Cobra II gamma counter(Packard, Meriden, Conn.). For each assay, spontaneous release from thetarget cells in the absence of effector CTL and maximum possible releaseafter treatment with 2% SDS (Baker Chemicals, Phillipsburg, N.J.) wasdetermined. Specific cytotoxicity was defined as: 100×[(Re−Rs)/Max−Rs)],where Re=experimental release, and Rs=spontaneous release. Chromiumrelease assays in which lysis without addition of peptide was 20% orgreater, or in which spontaneous lysis was 30% or more of the maximalrelease were considered unacceptable and not reported.

Example 5 Analysis of Individual Substitutions in Alanine SubstitutedPeptide Ligands

[0068] The alanine-substituted pp65₄₉₅₋₅₀₃ epitope peptides given inTable I were prepared as described in Example 1 using T2 cells as theantigen presenting targets. The nine peptide sequences were synthesizedwith either an amidated or free acid terminus. A terminal “C” in thepeptide name in Table I and in all following tables indicates a carboxylterminus whereas “N” indicates amide. The substitution of a native aminoacid for alanine is shown in bold for each position of the nonamerpeptide pp65₄₉₅₋₅₀₃. Peptide A7C corresponds to the native sequence(asterisk). These peptides were used to sensitive antigen presentingcells as described in Example 2 at concentrations of 0.05, 0.5 or 5 nM.The cells presenting these 18 peptides were used to test the T cellclone 3-3F4 by the standard four-hour chromium release assay describedin Example 4. Experiments were repeated twice on different days withsimilar results.

[0069] Results are shown in FIGS. 1 and 2. TABLE I Alanine ScanningLibrary of PP65₄₉₅₋₅₀₃ HCMV CTL Epitope. Position Peptide SEQ ID NO P1P2 P3 P4 P5 P6 P7 P8 P9 A1C  4 A L V P M V A T V A2C  5 N A V P M V A TV A3C  6 N L A P M V A T V A4C  7 N L V A M V A T V A5C  8 N L V P A V AT V A6C  9 N L V P M A A T V A7C*  1 N L V P M V A T V A8C 10 N L V P MV A A V A9C 11 N L V P M V A T A A1N 12 A L V P M V A T V A2N 13 N A V PM V A T V A3N 14 N L A P M V A T V A4N 15 N L V A M V A T V A5N 16 N L VP A V A T V A6N 17 N L V P M A A T V A7N 18 N L V P M V A T V A8N 19 N LV P M V A A V A9N 20 N L V P M V A T A

[0070] Substitution of alanine for asparagine at position 1, welltolerated by both the amidated and free acid forms of the peptide, basedon the slight change (compared to native) in recognition by the T cellclone. In every other position, except positions 8 and 9 for theamidated forms, there was a decline in recognition as a result ofalanine substitution of the native residue. The most precipitous decline(compared to native) in recognition occurred for peptides A3N-A6N(amidated analogs), and A3C A6C and A8C (free-acid analogs). In general,the amidated peptide analogs had a greater tolerance for alaninesubstitutions than the free acid forms. Substitution of the anchor atposition 9 by an alanine does not produce a substantial change incytotoxicity for the amidated form, whereas the equivalent free acidpeptide is severely impacted. In summary, positions 1-2 and 8-9 weremost tolerant of an alanine substitution as part of carboxyl amidatedpeptides whereas alanine substitution at positions 3-6 (positions3-6,8-9 for free acid analogs) caused a precipitous decrease inimmunogenicity.

[0071] The alanine-substitution study demonstrated plasticity in aminoacid residue substitution at several positions of the pp65₄₉₅₋₅₀₃ CTLepitope and suggests that the pp65₄₉₅₋₅₀₃ CTL epitope alanine-analogshave different recognition properties. Addition of an amide moiety tothe carboxyl terminus results in a peptide analog with increasedtolerance for alanine substitution in every position except position 5.

Example 6 Preparation of Positional Scanning Synthetic CombinatorialLibrary

[0072] Synthetic, C-amide (H-A1-Y9-CONH2) or C-hydroxyl (H-A1-Y9-COOH),L-amino acid combinatorial nonapeptide libraries arranged in apositional scanning format (PCT 97-3) were prepared according to priorart methods using the simultaneous multiple peptide synthesis method.Pinilla et al., Biotechniques 13:901-905 (1992). Each library consistedof 180 mixtures in the OX₈ format where O represents one each of the 20natural L-amino acids at a defined position and X represents any of the20 natural amino acids, with the exception of cysteine, in each of theremaining positions. The first mixture had alanine (A) in position 1(A₁X₈), while mixture number 180 had tyrosine (Y) in position 9 (X₈Y₉).Each OX₈ mixture therefore consisted of 1.7×10¹⁰ (198) different nonamerpeptides in approximate equimolar concentration, and the total Xglibrary consisted of 3.1×10¹² (9×20×198) different peptides. Assuming anaverage molecular weight of 1080 for each nonamer and a concentration of100 μg/ml (93 μM) for nonapeptides in a mixture, the averageconcentration of individual nonapeptides in a mixture was about5.5×10⁻¹⁵ M.

Example 7 PS-SCL Screen with T Cell Clone 3-3F4

[0073] To identify a nonapeptide or nonapeptides having greaterimmunogenicity than the native peptide, two different nonamer PS-SCLwere tested, one containing peptides with an amidated C-terminus, andthe other peptides with a free acid C-terminus. The library screeningwas carried out as follows. Separate aliquots of T2 cells were pulsedwith one of 180 mixtures (50 μg/ml) that make up the PS-SCL, andincubated with 3-3F4 cells as described in Example 2.

[0074] Two separate screenings were carried out on different days foreach test peptide mixture with similar results. Results from preliminaryexperiments (data not shown) showed that 5000 antigen presenting cellsat an E:T ratio of 5 was optimal, therefore, these conditions were usedto screen the PS-SCL. The results of the amidated nonapeptide PS-SCLscreen are shown in FIG. 3. All experimental points were obtained at thesame time, and results shown represent the average of two experimentsdone on different days. The amidated nonapeptide PS-SCL generally gavesignificantly better results; mixtures at each position resulted inspecific recognition and lysis. The variant peptides induced between 0and 90% specific cytotoxicity in the cells presenting them. Background(without peptide) was 5.0%. The highest specific cytotoxicity resultsfor each position were approximately equivalent to the results obtainedwith T2 antigen presenting cells pulsed with 1.0 and 10 nM nativepp65₄₉₅₋₅₀₃ epitope in a titration that was carried out simultaneouslywith the library screen (data not shown). In all positions the mixturehaving the defined amino acid that corresponds to the native peptideshowed specific lysis higher than 20%. The pp65₄₉₅₋₅₀₃ epitopesensitized 50% maximal lysis of T2 cells by 3-3F4 at 0.02 N, yet in manyinstances lysis exceeds 50%. There are striking levels of recognitionstimulated by one or mixtures at each position. The concentration ofeach peptide in the loading mixture is 95.5 fM, therefore the resultssuggest that one or more peptide(s) of high potency is responsible forthe activity of the mixture.

[0075] Mixtures defined with the native amino acids residues at theanchor positions 2 and 9 are among the highest responders at thosepositions, as expected. For example, the library screen indicates thatthe valine mixture for P9 is best recognized, which is identical to thenative epitope sequence. Interestingly, peptide mixtures with definedamino acids which were ranked slightly lower than valine at P9, wereeither of neutral charge, or contained aliphatic side chains, such asisoleucine, leucine, or alanine. Although leucine is considered analternative residue at position 9, its recognition in the screen wassubstantially less than valine. Mixtures having charged or more polaramino acids were ranked significantly lower, which confirms theirnon-preference as anchors for HLA A*0201 binding peptides. Although moreambiguous than in the case of P9, the higher ranked mixtures for P2(M,F,L) are also consistent with preferred residues for the P2 anchorposition based on published motifs. This result substantiates theconcept of using PS-SCL to modify this CTL epitope, because the screenaccurately predicted the sequence of the anchor residues forpp65₄₉₅₋₅₀₃.

[0076] For position 1, most mixtures show similar activities, rangingfrom 15-30% specific lysis, suggesting that a number of amino acids areacceptable at this position. The equivalence of these mixtures suggeststhat the F pocket of the MHC Class I binding groove can tolerate eitheran uncharged amino acid containing an aliphatic side chain, or amethionine (75).

[0077] Position 3 is occupied by valine in the native sequence. Mixturesdefined with the neutral amino acids leucine, methionine and isoleucineshowed higher activity than the valine mixture, while the alaninemixture was only slightly less active. The substantial difference inrecognition of the three highest ranked mixtures, compared to all otherssuggests a preference of those residues at position 3. The bestrecognized mixture for position 4 is proline, which is identical to thenative sequence. Mixtures defined with hydrophobic amino acids such astryptophan, isoleucine, and tyrosine were also active. The mixturechoice for position 5 is compatible with the native methionine residueor larger hydrophobic amino acids containing benzene rings (tryosine,tryptophan or phenylalanine). There is not a substantial difference inrecognition of the top 3 choices for position 5, nor is the level oflysis as high as the surrounding positions. Interestingly, themethionine at position 5 is negatively affected by any substitution,including alanine, among individually synthesized peptides. It is likelyoriented away from the MHC peptide binding pocket, making it availablefor TCR contact according to molecular modeling simulations (data notshown).

[0078] For position 6, the valine mixture is best recognized, and thesecond and third-ranked choices have fixed amino acids of similarstructure. Position 6 likely requires a small neutral-charged amino acidfor interaction with either MHC and/or TCR, independent of othersubstitutions. Between positions 7-9, the highest ranked mixtures aresignificantly better recognized than lower ranked ones. Position 7 andposition 8 provide the most dramatic difference between the highestranked mixtures, and those that follow. Significantly, mixtures whichcorrespond to the native amino acids are substantially less recognizedthan the preferred mixtures. For both positions 7 and 8, there is littlecorrelation between the ranking of subsequent mixtures and the structureof the fixed amino acid. The recognition of the alanine and threoninemixtures at P8 are equivalent (FIG. 3) which is consistent with resultsfrom the alanine-substitution study. The PS-SCL screen showed that thebest mixtures had either serine or proline at position 8. Table IIpresents the amino acid sequences of the peptides predicted by thescreen to bind to T cell clones more strongly than the native sequence.

[0079] Positions 1, 3, 6 and 9 were substituted with the fixed aminoacid corresponding to the top ranked mixture. In some cases, the top twoamino acids were selected (as for positions 4, 5, 7 and 8) when the toptwo ranked mixtures were recognized almost equivalently. The 16antigen-analogs were pulsed onto antigen presenting cells and evaluatedby conducting a chromium release assay with the screening T cell clone,3-3F4. The modified peptides were made as carboxyl-terminal amides, tobe consistent with the structure of the peptides contained in the PS-SCLscreening library. Two of the peptides were better recognized than thenative epitope sequence by the T cell clone. These peptides (46N and44N) were both tetra-substituted and were able to induce lysis atconcentrations lower than the native epitope. Examination of the commonelements of the sequence of peptides 44N and 46N, revealed a serine atposition 8. This amino acid resulted in the most potent of all 20 aminoacid sub-libraries tested at position 8 (FIG. 3). Interestingly,peptides 45 and 47, which share many of the substitutions of peptides 44and 46, but which contain a proline at position 8, were less active thanthe native sequence. Thus, the ranking of mixtures in the initial screenconforms to the recognition properties of the individual substitutionpeptides tested here. A re-screen of the same T cell clone (3-3F4) by aC-terminal free acid library resulted in uniformly low recognition ofall sub-libraries, even those having fixed amino acids that correspondto the native sequence (data not shown).

[0080] Peptides 44C and 46C were assayed to compare the sensitivity ofrecognition of the amide versus free acid form of the peptides.Unexpectedly, the absence of the carboxyl terminal amide eliminatedrecognition of both peptides by T cell clone 3-3F4 and all other T cellclone evaluated (data not shown). The native pp65₄₉₅₋₅₀₃ sequence wassynthesized with an amidated carboxyl terminus, and compared to the freeacid form by chromium release assay. The amidated peptide was recognizedwithout a significant change of activity compared to the free acidterminated sequence. See Table II. This is consistent with the resultsof the alanine substitution study which suggested that greaterflexibility of substitution is tolerated when the C-terminus is amidated(compare amidated to free acid results, Table II). TABLE II CytotoxicityResults from Potent Nonomer Peptides. Pep- tide SEQ ID Conc. Name NO P1P2 P3 P4 P5 P6 P7 P8 P9 (nM) 44N  2 Y L L P M V V S V 0.00005 46N  3 Y LL P M V T S V 0.0005 54N 21 Y L L W M V T S V 0.5 56N 22 Y L L W Y V V SV 50 47N 23 Y L L P M V T P V 500 52N 24 Y L L W M V V S V 500 53N 25 YL L W M V V P V 500 55N 26 Y L L W M V T P V 500 58N 27 Y L L W Y V T SV 500 45N 28 Y L L P M V V P V >500 48N 29 Y L L P Y V V S V >500 49N 30Y L L P Y V V P V >500 50N 31 Y L L P Y V T S V >500 51N 32 Y L L P Y VT P V >500 57N 33 Y L L W Y V V P V >500 59N 34 Y L L W Y V T P V >50044C 35 Y L L P M V V S V >500 46C 36 Y L L P M V T S V >500 A7N 18 N L VP M V A T V 0.5 A7C  1 N L V P M V A T V 0.5

Example 8 Cytotoxicity of Nonamer Peptides Predicted from PS-SCL Screen

[0081] The native sequence of the pp65₄₉₅₋₅₀₃ CTL epitope is shown atthe bottom of Table II. Substitutions predicted by the library screen ofT cell clone 3-3F4 are shown on top of the table below each residueposition of the CTL epitope. Peptides with carboxyl terminal amidationare named ending in “N,” while carboxyl terminal free acid peptides arenamed ending in “C.”

[0082] Nonamer peptides with the substitutions as shown at each positionwere synthesized as described in Example 1. Chromium release assays wereperformed using peptide sensitized HLA A*0201-restricted EBVLCL astarget cells and T cell clone 3-3F4 effectors at E:T=5. Results of theseassays are shown in the right-hand column of Table II, in terms ofconcentration of peptide (nM) in which specific killing was between 15and 30 percent. Results presented are the average from at least threeindependent experiments carried out on different days using differentbatches of T cell clone-3F4. Peptides were tested using 10-folddilutions, ranging from 500-0.00005 nM.

Example 9 T Cell Clone Flow-Cytometric Measurement of HLA-Ig DimerBinding to T Cell Clone Mediated by Antigen Analog and Control Peptides

[0083] HLA A2-Ig dimer aliquots were individually loaded with a seriesof peptides, and incubated with two different T cell clones, 3-3F4 andVB57. The soluble HLA-A2-Ig complexes (HLA dimers) were loaded withpeptide according to the methods of Greten et al., Proc. Natl. Acad.Sci. USA 95:7568-7573 (1998). For each peptide analog to be tested, 10μg of HLA dimers in 10 μl PBS containing 0.02% NaN₃ (Baker Chemical,Phillipsburg, N.J.) was incubated for three days at 4° C. with 660-foldmolar excess peptide. Dimers also were loaded with the pp65₄₉₅₋₅₀₃native peptide, an irrelevant peptide (pp54 B*0702 epitope), and 2 μlPBS buffer containing 0.02% NaN₃, in all experiments to serve ascontrols. One microgram aliquots of peptide loaded dimers were mixedwith 0.2 million of either T cell clone 3-3F4 or VB57 for 75 minutes onice. Cells were washed in PBS containing 2% FBS and 0.02% NaN₃ (WB), andsubsequently stained with 0.9 μl/sample of goat anti-mouse IgG₁-PE(Caltag, Burlingame, Calif.). After two additional washings in WB, cellswere analyzed by fluorescence-activated cell sorting (FACSCalibur™).Specific fluorescence was calculated as fluorescence ratio between themean fluorescence of the peptide-loaded diners and the mean fluorescenceof the buffer-loaded control diners. See FIG. 4. Peptides names endingin N are amidated, while those ending in C are free acids. Eachpeptide-loaded diner complex was tested at least twice with twodifferent T cell clones (3-3F4 and VB57). The fluorescence indicesindicated in the Figure are an average of both experiments. Measurementswith both cell lines were normalized, so they could be displayed on thesame axis.

[0084] Peptides 115 and 118, as well as the native sequence, pp65, boundwell to 3-3F4, although 44, 46 and 193 were unexpectedly poor binders.VB57 had a similar binding profile, except that 118 was a poor binder,and 193 was among the better binders. Interestingly, the free acid formsof binding peptides 115, 118 and 193 (VB57 only) failed to bind toeither T cell clone, in contrast to their amidated counterparts. Thefree acid 115, 118, and 193 peptides bound with similar affinity to thecontrol C-terminal free acid peptide derived from HIV pol protein. Thebinding data indicates that mechanisms other than TCR or MHC binding maycontribute to increased immunogenicity of these and other analogpeptides.

Example 10 Recognition of the pp65₄₉₅₋₅₀₃ CTL Epitope by HLA A*0201Donors

[0085] Ten randomly selected HCMV-seropositive, HLA A*0201⁺ healthydonors were selected for evaluation to confirm that the pp65₄₉₅₋₅₀₃ CTLepitope is widely recognized by HLA A*0201 persons. The haplotypes ofexamined individuals are shown in Table III. A one-step in vitrostimulation procedure modified from Lalvani et al., J. Immunol. Meth.210:65-77 (1997), was carried out utilizing the pp65495503 CTL epitope(SEQ ID NO:1) as the immunogen. See LaRosa et al., Blood 92(10, Suppl.1):518a (1998). In every case, the HLA A*0201 donors provoked a specificCTL response against T2 cells, and against HCMV-infected fibroblasts.See FIG. 5. AD169 strain HCMV was provided by J. Zaia (City of HopeMedical Center, COH). Virus stocks of 5-10×10⁶ pfu/ml were prepared fromthe supernatant of infected MRCvhbm5 fibroblasts as previously describedin Diamond et al., Blood 90:1751-1767 (1997) and used to infect dermalfibroblasts. Adherent cell lines were grown in fibroblast medium (FBM)consisting of D-MEM (Gibco, Rockville, Md.) supplemented with 10% FBS(Hyclone, Logan, Utah), 50 U/ml penicillin, 50 μg/ml streptomycin(Gibco, Rockville, Md.) and 2 mM L-glutamine (Gibco, Rockville, Md.).The results demonstrate that HCMV infection in HLA A*0201 positivehealthy donors stimulates a specific immune response to SEQ ID NO:1 thatis independent of haplotype, and likely to be universal in itsexpression. TABLE III Haplotypes of HCMV positive donors and TCRstructure of T Cell Clone isolated from PBMC evaluated by IVS. HLA HLAHLA HLA Donor A1 A2 B1 B2 TCC TCRA TCRB AA A2 A2 B44 B60 BS A2 A26 B51B62 BS25 AV2S1_(A2-)AJ45-AC BV7S2A1-BJ2.1-BC2 CM A2 A3 B7 B14 GL A2 A68B51 B60 3-3F4 AV18S2-AJ17.3-AC JE A2 A68 B7 N17 KKM A2 A1 B27 B44 LV A2A2 B51 B55 LVB ND ND NO A2 A3 B47 B51 RB A2 A2 B52 B60 TG A2 A68 B62 B62TGA2 AV3S1-AJ9.12-AC BV13S2A1-BJ2.1-BC2 VB A2 A3 B44 B62 VB57AV18S1-AJ20-C BV20S1A3-BJ1.1-BC1

Example 11 Enhanced Immunogenicity Peptide Analogs with RetainedUniversal Recognition

[0086] The PS-SCL library screen results pointed to two peptides(numbers 44N and 46N) recognized by the HLA A*0201-restricted T cellclone 3-3F4 with greater affinity than the native epitope. To testwhether this increase in binding is common to all T cell clones whichrecognized the native epitope, a chromium release assay was performedusing a cohort of four additional T cell clones derived from fourdifferent HCMV-seropositive volunteers and donor GL, from whom the clone3-3F4 was obtained. Peptide analogs 44 and 46 were not recognized by anyof the T cell clones in the cohort (data not shown).

[0087] To confirm that a T cell repertoire which recognizes peptides 44,46 or both could be stimulated from a population of cells obtained fromHCMV-seropositive individuals, the peripheral blood of four individualswas stimulated in vitro using peptides 44 and 46 (data not shown). DonorGL had cross-reactive T cells which were amplified by peptides 44 and46, however, none of the other donors did.

[0088] To take advantage of the increased immunogenicity of peptides 44and 46, while maintaining the universal recognition of the nativepeptide, library-directed changes were made to peptides 44 and 46,substituting back the native amino acids. A series of 21 peptides wereconstructed based upon the sequence of the tetra-substituted peptides 44and 46 in each of the carboxyl terminal amidated and free acid forms.See Table IV. The peptides contained single, double, or triplesubstitutions of amino acids of the native sequence at the positionsindicated. These peptides were assayed utilizing a standard chromiumrelease assay with the screening T cell clone, 3-3F4, and arepresentative T cell clone (VB57) from another individual expressing adifferent T cell receptor.

[0089] Fifteen of the 21 amidated peptides were recognized by T cellclone 3-F4 at a lower concentration than the native epitope (Table IIabove), but only five were 100-fold or more active (Table IV). The freeacid forms of the same peptide sequences were generally less potent. Forexample, peptide 193C (free acid) was approximately 100-fold lessreactive than the native epitope, while peptide 193N (amide) wasapproximately 100-fold more immunogenic than the native epitope. Sevenof the amidated peptides were recognized with a specific cytotoxicity ofgreater than 15% at a concentration of 0.05 nM, which is a greatersensitivity than the native epitope has for the same T cell clone. Onlyone of the free acid peptides was immunogenic below 0.05 nM, however.This peptide (111C) was equivalent to its amidated counterpart. SeeTable IV. These results further confirm that amidation of the carboxylterminus of nonamer peptides provides greater flexibility forrecognition. TABLE IV Substituted Carboxyl Terminal Amide and Free AcidPeptide Sequences Developed from Peptides 44 and 46. Position 1 2 3 4 56 7 8 9 T Cell Clone Peptide A Amide Free Acid Name; N V T T 3-3F4 VB573-3F4 VB57 SEQ ID NO Y L L P M V V S V Peptide Concentration (nM) 193N;37 Y L V P M V A T V 0.005 0.05 >5 >5 193C; 38 194N; 39 N L L P M V A TV 0.05 0.5 >5 >5 194C; 40 110N; 41 N L V P M V V T V 0.05 >5 0.5 ND110C; 42 111N; 43 N L V P M V T T V 0.05 >5 0.05 5 111C; 44 112N; 45 N LV P M V A S V 0.5 0.5 5 0.5 112C; 46 116N; 47 N L L P M V V T V0.5 >5 >5 ND 116C; 48 117N; 49 N L L P M V T T V 0.05 >5 0.5 5 117C; 50118N; 51 N L L P M V A S V 0.05 0.05 >5 >5 118C; 52 119N; 53 N L V P M VV S V 0.005 >5 >5 >5 119C; 54 120N; 55 N L V P M V T S V 0.05 >5 5 >5120C; 56 195N; 57 Y L L P M V A T V 0.005 0.5 >5 >5 195C; 58 113N; 59 YL V P M V V T V 0.5 >5 >5 ND 113C; 60 114N; 61 Y L V P M V T T V 0.05 50.5 5 114C; 62 115N; 63 Y L V P M V A S V 0.005 0.05 >5 5 115C; 64 126N;65 N L L P M V V S V 0.005 0.5 5 >5 126C; 66 127N; 67 N L L P M V T S V0.05 >5 5 >5 127C; 68 124N; 69 Y L V P M V V S V 0.5 5 >5 >5 124C; 70125N; 71 Y L V P M V T S V 0.05 >5 >5 >5 125C; 72 121N; 73 Y L L P M V VT V 5 >5 >5 ND 121C; 74 122N; 75 Y L L P M V T T V 5 >5 >5 >5 122C; 76123N; 77 Y L L P M V A S V 0.05 0.5 >5 >5 123C; 78

[0090] The amino acid substitutions that resulted in increasedrecognition by T cell clone 3-3F4 can be consolidated into a fewcategories. Most striking is the substitution of tyrosine for asparagineat position 1, which is present in three of the five most immunogenicpeptides. Even as a single substitution it provides a 100-fold increasein reactivity compared to the native epitope. The substitution of serineat position 8 also is present in three of the five highest rankingpeptides recognized by 3-3F4. There is no clear pattern within the 21peptides, however, so it is not possible to predict which substitutionswill be effective without screening all of the possible combinations.

[0091] T cell clone VB57, which expresses a different TCR than 3-3F4,evoked a different spectrum of responses (Table IV). Three peptidesequences (115N, 118N and 193N; SEQ ID NOS: 64, 52 and 38) arerecognized with greater sensitivity by both T cell clones, and wereconsidered candidate CTL epitope vaccines. These results demonstratethat it is possible to engineer peptides with enhanced recognition tomultiple T cell clones.

[0092] The antigen analogs best recognized by both T cell clones 3-3F4and VB57 (115N, 118N and 193N) were evaluated for recognition by acohort of 3-3F4, VB57 and three additional T cell clones from threeindividuals. The T cell clones were stimulated in vitro with the nativesequence of pp65₄₉₅₋₅₀₃ (SEQ ID NO:1) as described in Example 2.Limiting dilution cloning was conducted with a portion of the cells, andindividual clones were evaluated using chromium release assays with thepeptides indicated in Table V. The amount of peptide used to sensitizeHLA A*0201-expressing EBVLCL target cells was 5.0 or 0.5 nM. Filledboxes indicate >30% specific cytotoxicity. Peptide 118 resulted ingreater specific cytotoxicity at a lower concentration than the nativesequence in three out of five T cell clones. Peptides 115 and 193resulted in more potent lysis in two out of five T cell clones. For thebest peptides, the sensitivity of T cell recognition is at least 10times greater than the native epitope, although there were cases whenthe recognition is merely equivalent. These data confirm that thesederived sequences were better recognized than the native CTL epitope,but still were recognized by a large number of T cell clones withdifferently expressed TCRs. TABLE V Recognition of Peptides by T CellClones from HLA A*0201 Individuals Seropositive for HHCMV. NativePeptide Peptide Peptide sequence 115 118 193 T Cell Clone 5.0 nM 0.5 nM5.0 nM 0.5 nM 5.0 nM 0.5 nM 5.0 nM 0.5 nM GL 3-3F7 VB 57 BS 25 LV B TG 2

Example 12 Recognition of Antigen Analogs by Multiple T Cell Clones

[0093] Peripheral blood from separate individuals was stimulated withpeptides 115, 118, and 193 and subjected to a chromium release assay.Aliquots of magnetically-depleted lymphocytes were incubated withautologous antigen presenting cells loaded with one of four amidatedpeptides (SEQ ID NO:1; results not shown) under in vitro stimulationconditions as described above. Lymphocytes from three individuals wereused for all four peptides, including SEQ ID NO:1, and one individual(BS) was evaluated with 193 peptide and the positive control. T cellclones from three individuals vigorously responded to the in vitrostimulation conducted with all three peptides. See FIG. 6. Peptides 118and 193 were recognized by all evaluated individuals, whereas peptide115 was recognized in three out of five individuals. Effector cells fromthe cultures of three individuals specifically recognized HCMV-infectedfibroblasts after stimulation by all three peptides.

Example 13 MHC Binding Affinity of Antigen Analogs by T2 Assembly Assay.

[0094] Five analog peptides and the native sequence were evaluated foraffinity to HLA A*0201 as both free acids and amides by T2 assemblyassay. See the methods of Nijman et al., Eur. J. Immunol. 23:1215-1219(1993). A known HLA A*0201 binding peptide served as control.

[0095] T2 cells, which express HLA-A*0201 molecules, were cultured inIMDM (Gibco, Rockville, Md.) with supplements as described for EBVLCL.For each analog to be tested, 250,000 T2 cells were washed twice andresuspended in serum free IMDM and incubated overnight with 100 μMpeptide together with 15 μg/ml human β₂-microglobulin (Sigma, Lt. Louis,Mo.) at 37° C. in a 5% CO₂ incubator. Peptide loaded cells were washedonce at 4° C. with cold PBS containing 0.05% BSA (Sigma, St.; Louis,Mo.) and 0.02% NaN₃ followed by incubation with 1 μg/sample murine mAbBB7.2, an antibody specific for cell-surface HLA A*0201 (ATCC), for 30minutes at 4° C. After washing twice with cold buffer, FITC-conjugatedrat anti-mouse IgG_(2a/2b) (1:40 dilution; Pharmingen, San Diego,Calif.) was added and incubated for another 30 minutes at 4° C. Thecells were washed twice in cold buffer, and mean fluorescence intensity(MFI) of 10⁴ gated cells was measured using a FACSCalibur™.

[0096] Representative results from three separate measurements are shownin FIG. 7. Fluorescence ratio is defined as mean fluorescence withpeptide/mean fluorescence without peptide. Results for the amidatedpeptides indicate only slight changes in MHC binding. Ranking amidatedpeptides according to strength of MHC binding does not reveal a patternthat would explain the restricted recognition of peptides 44 and 46versus the native sequence. Although peptides 44 and 46 have been shownto be strongly immunogenic to T cell clone 3-3F4, their MHC affinitymeasured by this assay is not dramatically different from the nativesequence. This indicates that the reason for the enhanced immunogenicityof these two peptides does not relate to affinity to HLA Class I.

1 78 1 9 PRT Human cytomegalovirus 1 Asn Leu Val Pro Met Val Ala Thr Val1 5 2 9 PRT Artificial Sequence HCMV vaccine peptide 2 Tyr Leu Leu ProMet Val Val Ser Val 1 5 3 9 PRT Artificial Sequence HCMV vaccine peptide3 Tyr Leu Leu Pro Met Val Thr Ser Val 1 5 4 9 PRT Artificial SequenceHCMV vaccine peptide 4 Ala Leu Val Pro Met Val Ala Thr Val 1 5 5 9 PRTArtificial Sequence HCMV vaccine peptide 5 Asn Ala Val Pro Met Val AlaThr Val 1 5 6 9 PRT Artificial Sequence HCMV vaccine peptide 6 Asn LeuAla Pro Met Val Ala Thr Val 1 5 7 9 PRT Artificial Sequence HCMV vaccinepeptide 7 Asn Leu Val Ala Met Val Ala Thr Val 1 5 8 9 PRT ArtificialSequence HCMV vaccine peptide 8 Asn Leu Val Pro Ala Val Ala Thr Val 1 59 9 PRT Artificial Sequence HCMV vaccine peptide 9 Asn Leu Val Pro MetAla Ala Thr Val 1 5 10 9 PRT Artificial Sequence HCMV vaccine peptide 10Asn Leu Val Pro Met Val Ala Ala Val 1 5 11 9 PRT Artificial SequenceHCMV vaccine peptide 11 Asn Leu Val Pro Met Val Ala Thr Ala 1 5 12 9 PRTArtificial Sequence HCMV vaccine peptide 12 Ala Leu Val Pro Met Val AlaThr Val 1 5 13 9 PRT Artificial Sequence HCMV vaccine peptide 13 Asn AlaVal Pro Met Val Ala Thr Val 1 5 14 9 PRT Artificial Sequence HCMVvaccine peptide 14 Asn Leu Ala Pro Met Val Ala Thr Val 1 5 15 9 PRTArtificial Sequence HCMV vaccine peptide 15 Asn Leu Val Ala Met Val AlaThr Val 1 5 16 9 PRT Artificial Sequence HCMV vaccine peptide 16 Asn LeuVal Pro Ala Val Ala Thr Val 1 5 17 9 PRT Artificial Sequence HCMVvaccine peptide 17 Asn Leu Val Pro Met Ala Ala Thr Val 1 5 18 9 PRTArtificial Sequence HCMV vaccine peptide 18 Asn Leu Val Pro Met Val AlaThr Val 1 5 19 9 PRT Artificial Sequence HCMV vaccine peptide 19 Asn LeuVal Pro Met Val Ala Ala Val 1 5 20 9 PRT Artificial Sequence HCMVvaccine peptide 20 Asn Leu Val Pro Met Val Ala Thr Ala 1 5 21 9 PRTArtificial Sequence HCMV vaccine peptide 21 Tyr Leu Leu Trp Met Val ThrSer Val 1 5 22 9 PRT Artificial Sequence HCMV vaccine peptide 22 Tyr LeuLeu Trp Tyr Val Val Ser Val 1 5 23 9 PRT Artificial Sequence HCMVvaccine peptide 23 Tyr Leu Leu Pro Met Val Thr Pro Val 1 5 24 9 PRTArtificial Sequence HCMV vaccine peptide 24 Tyr Leu Leu Trp Met Val ValSer Val 1 5 25 9 PRT Artificial Sequence HCMV vaccine peptide 25 Tyr LeuLeu Trp Met Val Val Pro Val 1 5 26 9 PRT Artificial Sequence HCMVvaccine peptide 26 Tyr Leu Leu Trp Met Val Thr Pro Val 1 5 27 9 PRTArtificial Sequence HCMV vaccine peptide 27 Tyr Leu Leu Trp Tyr Val ThrSer Val 1 5 28 9 PRT Artificial Sequence HCMV vaccine peptide 28 Tyr LeuLeu Pro Met Val Val Pro Val 1 5 29 9 PRT Artificial Sequence HCMVvaccine peptide 29 Tyr Leu Leu Pro Tyr Val Val Ser Val 1 5 30 9 PRTArtificial Sequence HCMV vaccine peptide 30 Tyr Leu Leu Pro Tyr Val ValPro Val 1 5 31 9 PRT Artificial Sequence HCMV vaccine peptide 31 Tyr LeuLeu Pro Tyr Val Thr Ser Val 1 5 32 9 PRT Artificial Sequence HCMVvaccine peptide 32 Tyr Leu Leu Pro Tyr Val Thr Pro Val 1 5 33 9 PRTArtificial Sequence HCMV vaccine peptide 33 Tyr Leu Leu Trp Tyr Val ValPro Val 1 5 34 9 PRT Artificial Sequence HCMV vaccine peptide 34 Tyr LeuLeu Trp Tyr Val Thr Pro Val 1 5 35 9 PRT Artificial Sequence HCMVvaccine peptide 35 Tyr Leu Leu Pro Met Val Val Ser Val 1 5 36 9 PRTArtificial Sequence HCMV vaccine peptide 36 Tyr Leu Leu Pro Met Val ThrSer Val 1 5 37 9 PRT Artificial Sequence HCMV vaccine peptide 37 Tyr LeuVal Pro Met Val Ala Thr Val 1 5 38 9 PRT Artificial Sequence HCMVvaccine peptide 38 Tyr Leu Val Pro Met Val Ala Thr Val 1 5 39 9 PRTArtificial Sequence HCMV vaccine peptide 39 Asn Leu Leu Pro Met Val AlaThr Val 1 5 40 9 PRT Artificial Sequence HCMV vaccine peptide 40 Asn LeuLeu Pro Met Val Ala Thr Val 1 5 41 9 PRT Artificial Sequence HCMVvaccine peptide 41 Asn Leu Val Pro Met Val Val Thr Val 1 5 42 9 PRTArtificial Sequence HCMV vaccine peptide 42 Asn Leu Val Pro Met Val ValThr Val 1 5 43 9 PRT Artificial Sequence HCMV vaccine peptide 43 Asn LeuVal Pro Met Val Thr Thr Val 1 5 44 9 PRT Artificial Sequence HCMVvaccine peptide 44 Asn Leu Val Pro Met Val Thr Thr Val 1 5 45 9 PRTArtificial Sequence HCMV vaccine peptide 45 Asn Leu Val Pro Met Val AlaSer Val 1 5 46 9 PRT Artificial Sequence HCMV vaccine peptide 46 Asn LeuVal Pro Met Val Ala Ser Val 1 5 47 9 PRT Artificial Sequence HCMVvaccine peptide 47 Asn Leu Leu Pro Met Val Val Thr Val 1 5 48 9 PRTArtificial Sequence HCMV vaccine peptide 48 Asn Leu Leu Pro Met Val ValThr Val 1 5 49 9 PRT Artificial Sequence HCMV vaccine peptide 49 Asn LeuLeu Pro Met Val Thr Thr Val 1 5 50 9 PRT Artificial Sequence HCMVvaccine peptide 50 Asn Leu Leu Pro Met Val Thr Thr Val 1 5 51 9 PRTArtificial Sequence HCMV vaccine peptide 51 Asn Leu Leu Pro Met Val AlaSer Val 1 5 52 9 PRT Artificial Sequence HCMV vaccine peptide 52 Asn LeuLeu Pro Met Val Ala Ser Val 1 5 53 9 PRT Artificial Sequence HCMVvaccine peptide 53 Asn Leu Val Pro Met Val Val Ser Val 1 5 54 9 PRTArtificial Sequence HCMV vaccine peptide 54 Asn Leu Val Pro Met Val ValSer Val 1 5 55 9 PRT Artificial Sequence HCMV vaccine peptide 55 Asn LeuVal Pro Met Val Thr Ser Val 1 5 56 9 PRT Artificial Sequence HCMVvaccine peptide 56 Asn Leu Val Pro Met Val Thr Ser Val 1 5 57 9 PRTArtificial Sequence HCMV vaccine peptide 57 Tyr Leu Leu Pro Met Val AlaThr Val 1 5 58 9 PRT Artificial Sequence HCMV vaccine peptide 58 Tyr LeuLeu Pro Met Val Ala Thr Val 1 5 59 9 PRT Artificial Sequence HCMVvaccine peptide 59 Tyr Leu Val Pro Met Val Val Thr Val 1 5 60 9 PRTArtificial Sequence HCMV vaccine peptide 60 Tyr Leu Val Pro Met Val ValThr Val 1 5 61 9 PRT Artificial Sequence HCMV vaccine peptide 61 Tyr LeuVal Pro Met Val Thr Thr Val 1 5 62 9 PRT Artificial Sequence HCMVvaccine peptide 62 Tyr Leu Val Pro Met Val Thr Thr Val 1 5 63 9 PRTArtificial Sequence HCMV vaccine peptide 63 Tyr Leu Val Pro Met Val AlaSer Val 1 5 64 9 PRT Artificial Sequence HCMV vaccine peptide 64 Tyr LeuVal Pro Met Val Ala Ser Val 1 5 65 9 PRT Artificial Sequence HCMVvaccine peptide 65 Asn Leu Leu Pro Met Val Val Ser Val 1 5 66 9 PRTArtificial Sequence HCMV vaccine peptide 66 Asn Leu Leu Pro Met Val ValSer Val 1 5 67 9 PRT Artificial Sequence HCMV vaccine peptide 67 Asn LeuLeu Pro Met Val Thr Ser Val 1 5 68 9 PRT Artificial Sequence HCMVvaccine peptide 68 Asn Leu Leu Pro Met Val Thr Ser Val 1 5 69 9 PRTArtificial Sequence HCMV vaccine peptide 69 Tyr Leu Val Pro Met Val ValSer Val 1 5 70 9 PRT Artificial Sequence HCMV vaccine peptide 70 Tyr LeuVal Pro Met Val Val Ser Val 1 5 71 9 PRT Artificial Sequence HCMVvaccine peptide 71 Tyr Leu Val Pro Met Val Thr Ser Val 1 5 72 9 PRTArtificial Sequence HCMV vaccine peptide 72 Tyr Leu Val Pro Met Val ThrSer Val 1 5 73 9 PRT Artificial Sequence HCMV vaccine peptide 73 Tyr LeuLeu Pro Met Val Val Thr Val 1 5 74 9 PRT Artificial Sequence HCMVvaccine peptide 74 Tyr Leu Leu Pro Met Val Val Thr Val 1 5 75 9 PRTArtificial Sequence HCMV vaccine peptide 75 Tyr Leu Leu Pro Met Val ThrThr Val 1 5 76 9 PRT Artificial Sequence HCMV vaccine peptide 76 Tyr LeuLeu Pro Met Val Thr Thr Val 1 5 77 9 PRT Artificial Sequence HCMVvaccine peptide 77 Tyr Leu Leu Pro Met Val Ala Ser Val 1 5 78 9 PRTArtificial Sequence HCMV vaccine peptide 78 Tyr Leu Leu Pro Met Val AlaSer Val 1 5

1. A vaccine which comprises a peptide selected from the groupconsisting of SEQ ID NOs: 38, 52 and
 64. 2. A vaccine of claim 1 whichfurther comprises an adjuvant.
 3. A vaccine of claim 2, wherein saidadjuvant is a DNA adjuvant.
 4. A vaccine of claim 3, wherein said DNAadjuvant is a CpG DNA adjuvant.